SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?
Status: | Active, not recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 60 - 80 |
Updated: | 1/27/2019 |
Start Date: | July 2015 |
End Date: | March 2020 |
The purpose of this study is to compare health-related quality of life (HRQOL) outcomes in
older (60-80 years) advanced heart failure (HF) patients who undergo heart transplantation
(HT) or mechanical circulatory support (MCS) as a permanent implant (i.e., destination
therapy [DT]) and their caregivers. Our study will contribute to better patient-centered care
of older advanced HF patients and their caregivers, by informing decision making and guiding
strategies to enhance post-operative HRQOL.
older (60-80 years) advanced heart failure (HF) patients who undergo heart transplantation
(HT) or mechanical circulatory support (MCS) as a permanent implant (i.e., destination
therapy [DT]) and their caregivers. Our study will contribute to better patient-centered care
of older advanced HF patients and their caregivers, by informing decision making and guiding
strategies to enhance post-operative HRQOL.
The purpose of this study is to compare health-related quality of life (HRQOL) outcomes in
older (60-80 years) advanced heart failure (HF) patients who undergo heart transplantation
(HT) or mechanical circulatory support (MCS) as a permanent implant (i.e., destination
therapy [DT]) and their caregivers, risk factors for poor HRQOL, adverse event and symptom
burden, and quality-adjusted life years (QALYs). Advanced HF patients, 60-80 years of age,
are an appropriate target group for this study because they are receiving HTs and MCS devices
more frequently, and despite a greater risk for poor clinical outcomes, they have acceptable
rates of survival. Using a prospective, longitudinal design, our multi-site comparative
effectiveness research will compare HRQOL outcomes in patients who receive HT or DT MCS and
their caregivers, from baseline to 2 years post-operatively. The primary aim of this proposed
study is to determine whether older advanced HF patients who undergo DT MCS, as compared to
patients who undergo HT, experience non-inferior change in overall HRQOL (primary), and
domains of HRQOL (physical, mental, and social) from baseline through 2 years after surgery.
Secondary Aims are (1.) to determine whether caregivers of older advanced HF patients who
undergo DT MCS, compared to caregivers of older advanced HF patients who undergo HT,
experience non-inferior change in overall HRQOL and domains from baseline through 2 years
after surgery; (2.-3.) to identify risk factors related to poorer overall HRQOL in older DT
MCS patients and their caregivers, as compared to older HT patients and their caregivers, at
2 years after surgery; (4.) to determine whether older advanced HF patients who undergo DT
MCS, as compared to patients who undergo HT, have non-inferior rates of freedom from adverse
events & symptoms at 1 and 2 years after surgery; and (5) to evaluate the distribution of
QALYs in older advanced HF patients who undergo DT MCS, as compared to patients who undergo
HT at 2 years after surgery. Our proposed study will contribute to better patient-centered
care of older advanced HF patients and their caregivers, by informing decision making and
guiding strategies to enhance post-operative HRQOL.
older (60-80 years) advanced heart failure (HF) patients who undergo heart transplantation
(HT) or mechanical circulatory support (MCS) as a permanent implant (i.e., destination
therapy [DT]) and their caregivers, risk factors for poor HRQOL, adverse event and symptom
burden, and quality-adjusted life years (QALYs). Advanced HF patients, 60-80 years of age,
are an appropriate target group for this study because they are receiving HTs and MCS devices
more frequently, and despite a greater risk for poor clinical outcomes, they have acceptable
rates of survival. Using a prospective, longitudinal design, our multi-site comparative
effectiveness research will compare HRQOL outcomes in patients who receive HT or DT MCS and
their caregivers, from baseline to 2 years post-operatively. The primary aim of this proposed
study is to determine whether older advanced HF patients who undergo DT MCS, as compared to
patients who undergo HT, experience non-inferior change in overall HRQOL (primary), and
domains of HRQOL (physical, mental, and social) from baseline through 2 years after surgery.
Secondary Aims are (1.) to determine whether caregivers of older advanced HF patients who
undergo DT MCS, compared to caregivers of older advanced HF patients who undergo HT,
experience non-inferior change in overall HRQOL and domains from baseline through 2 years
after surgery; (2.-3.) to identify risk factors related to poorer overall HRQOL in older DT
MCS patients and their caregivers, as compared to older HT patients and their caregivers, at
2 years after surgery; (4.) to determine whether older advanced HF patients who undergo DT
MCS, as compared to patients who undergo HT, have non-inferior rates of freedom from adverse
events & symptoms at 1 and 2 years after surgery; and (5) to evaluate the distribution of
QALYs in older advanced HF patients who undergo DT MCS, as compared to patients who undergo
HT at 2 years after surgery. Our proposed study will contribute to better patient-centered
care of older advanced HF patients and their caregivers, by informing decision making and
guiding strategies to enhance post-operative HRQOL.
Patient Inclusion Criteria:
1. Advanced HF and listed with the United Network for Organ Sharing (UNOS) for a
"primary" HT or scheduled to receive a "primary" DT LVAD;
2. Ages 60-80 years and able to speak, read, and understand English;
3. Willing to participate and ability to provide informed consent.
Caregiver Inclusion criteria:
1. Primary caregiver, identified by the patient, prior to DT MCS or while a candidate for
HT;
2. Unpaid family member or friend who helps the patient with self-care;
3. Age > 21 years and able to speak, read, and write English;
4. Willing to participate and ability to provide informed consent.
Patient Exclusion criteria
1. Patient has a prior HT or MCS device
2. Patient is listed for multiple organ transplantation (i.e., heart/lung, heart/kidney,
etc.)
Caregiver Exclusion criterion:
1) Patient refusal to participate.
We found this trial at
13
sites
Kansas City, Missouri 64111
Principal Investigator: Andrew Kao, MD
Phone: 816-932-1627
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Eileen Hsich, MD
Phone: 216-445-1174
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
New York, New York 10027
(212) 854-1754
Principal Investigator: Koji Takeda, MD
Phone: 212-342-2104
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Francis Pagani, MD, PhD
Phone: 734-647-7958
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Salpy Pamboukian, MD
Phone: 205-975-8511
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Kathleen Grady, RN, PhD
Phone: 312-926-2828
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Brent Lampert, DO
Phone: 614-366-8848
Click here to add this to my saved trials
Madison, Wisconsin 53706
(608) 263-2400
Principal Investigator: Maryl Johnson, MD
Phone: 608-262-7115
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials
Minneapolis, Minnesota 55454
Principal Investigator: Michael Petty, PhD, APRN-CN
Phone: 612-626-2989
Click here to add this to my saved trials
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
Orlando, Florida 32803
(407) 303-5600
Principal Investigator: Scott Silvestry, MD
Phone: 407-303-7120
Florida Hospital Florida Hospital is one of the country
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Mary Amanda Dew, PhD
Phone: 412-624-3373
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Shane LaRue, MD
Phone: 314-454-7422
Click here to add this to my saved trials